Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 6/2013

01.12.2013 | ORIGINAL ARTICLE

Anti-Atherogenic Effects of Methotrexate Carried by a Lipid Nanoemulsion That Binds to LDL Receptors in Cholesterol-fed Rabbits

verfasst von: Adriana Bulgarelli, Antonio C. A. Leite Jr, Adriana A. M. Dias, Raul C. Maranhão

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Nanoemulsions (LDE) with a lipid composition resembling that of LDL can concentrate in aortic lesions and when associated with anti-blastic agents, such as paclitaxel or etoposide, decrease atherosclerotic lesions induced in rabbits. Our aim was to test the association of a lipophilic derivative of methotrexate, didodecyl-methotrexate (ddMTX) to LDE on the lesions and on the expression of pro-inflammatory and anti-inflammatory genes.

Methods

Twenty male New Zealand rabbits were fed 1 % cholesterol diet for 60 days. Starting from day 30, 10 animals were treated with 4 weekly LDE-ddMTX injections (4 mg/kg, I.V.) and 10 with LDE injections (20 mg LDE total lipid mass/kg).

Results

LDE-ddMTX reduced the size of the lesion areas by 65 % and the intima–media ratio by 2-fold. Reduction of intimal macrophage was 67 % and of apoptotic cells was 88 %. Smooth muscle cells migration into the intima was unaffected. LDE-ddMTX treatment diminished metalloproteinase-9 in the intima. In aortas of atherosclerotic rabbits, downregulation of 6 pro-inflammatory genes, TNF-α, MCP-1, IL-1β, IL-18, MMP-9, MMP-12 and upregulation of the anti-inflammatory IL-10 gene were observed. Incubation of LDE-ddMTX with HUVEC cells led to downregulation of TNF-α IL1-β VAP-1, TLR2 and CXCL2.

Conclusions

LDE-ddMTX is potentially useful to threat atherosclerosis by acting on inflammatory processes which are instrumental in the development of the disease.
Literatur
1.
Zurück zum Zitat Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 2010;7:77–86.PubMedCrossRef Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 2010;7:77–86.PubMedCrossRef
2.
Zurück zum Zitat Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov. 2011;10:365–76.PubMedCrossRef Charo IF, Taub R. Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov. 2011;10:365–76.PubMedCrossRef
3.
Zurück zum Zitat Sitia S, Atzeni F, Sarzi-Puttini P, Di Bello V, Tomasoni L, Delfino L, et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev. 2009;8:281–6.PubMedCrossRef Sitia S, Atzeni F, Sarzi-Puttini P, Di Bello V, Tomasoni L, Delfino L, et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev. 2009;8:281–6.PubMedCrossRef
4.
Zurück zum Zitat Bulgarelli A, Martins Dias AA, Caramelli B, Maranhão RC. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol. 2012;59:308–14.PubMedCrossRef Bulgarelli A, Martins Dias AA, Caramelli B, Maranhão RC. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol. 2012;59:308–14.PubMedCrossRef
5.
Zurück zum Zitat Maranhão RC, Roland IA, Toffoletto O, Ramires JA, Gonçalves RP, Mesquita CH, et al. Plasma kinetic behavior in hyperlipidemic subjects of a lipidic microemulsion that binds to low density lipoprotein receptors. Lipids. 1997;32:627–33.PubMedCrossRef Maranhão RC, Roland IA, Toffoletto O, Ramires JA, Gonçalves RP, Mesquita CH, et al. Plasma kinetic behavior in hyperlipidemic subjects of a lipidic microemulsion that binds to low density lipoprotein receptors. Lipids. 1997;32:627–33.PubMedCrossRef
6.
Zurück zum Zitat Ruiz J, Kouiavskaia D, Migliorini M, Robinson S, Saenko EL, Gorlatova N, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res. 2005;46:1721–31.PubMedCrossRef Ruiz J, Kouiavskaia D, Migliorini M, Robinson S, Saenko EL, Gorlatova N, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res. 2005;46:1721–31.PubMedCrossRef
7.
Zurück zum Zitat Hirata RD, Hirata MH, Mesquita CH, Cesar TB, Maranhão RC. Effects of apolipoprotein B-100 on the metabolism of a lipid microemulsion model in rats. Biochim Biophys Acta. 1999;1437:53–62.PubMedCrossRef Hirata RD, Hirata MH, Mesquita CH, Cesar TB, Maranhão RC. Effects of apolipoprotein B-100 on the metabolism of a lipid microemulsion model in rats. Biochim Biophys Acta. 1999;1437:53–62.PubMedCrossRef
8.
Zurück zum Zitat Dias ML, Carvalho JP, Rodrigues DG, Graziani SR, Maranhão RC. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol rich nanoemulsion in patients with gynecologic cancers. Cancer Chemother Pharmacol. 2007;59:105–11.PubMedCrossRef Dias ML, Carvalho JP, Rodrigues DG, Graziani SR, Maranhão RC. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol rich nanoemulsion in patients with gynecologic cancers. Cancer Chemother Pharmacol. 2007;59:105–11.PubMedCrossRef
9.
Zurück zum Zitat Maranhão RC, Garicochea B, Silva EL, Dorlhiac-Llacer P, Cadena SM, Coelho IJ, et al. Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res. 1994;54:4660–6.PubMed Maranhão RC, Garicochea B, Silva EL, Dorlhiac-Llacer P, Cadena SM, Coelho IJ, et al. Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res. 1994;54:4660–6.PubMed
10.
Zurück zum Zitat Valduga CJ, Fernandes DC, Lo Prete AC, Azevedo CHM, Rodrigues DG, Maranhao RC. Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide. J Pharm Pharmacol. 2003;55:1615–22.PubMedCrossRef Valduga CJ, Fernandes DC, Lo Prete AC, Azevedo CHM, Rodrigues DG, Maranhao RC. Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide. J Pharm Pharmacol. 2003;55:1615–22.PubMedCrossRef
11.
Zurück zum Zitat Maranhao RC, Tavares ER, Padoveze AF, Valduga CJ, Rodrigues DG, Pereira MD. Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit. Atherosclerosis. 2008;197:959–66.PubMedCrossRef Maranhao RC, Tavares ER, Padoveze AF, Valduga CJ, Rodrigues DG, Pereira MD. Paclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbit. Atherosclerosis. 2008;197:959–66.PubMedCrossRef
12.
Zurück zum Zitat Moura JA, Valduga CJ, Tavares ER, Kretzer IF, Maria DA, Maranhão RC. Novel formulation of a methotrexate derivative with a lipid nanoemulsion. Int J Nanomed. 2011;6:2285–95. Moura JA, Valduga CJ, Tavares ER, Kretzer IF, Maria DA, Maranhão RC. Novel formulation of a methotrexate derivative with a lipid nanoemulsion. Int J Nanomed. 2011;6:2285–95.
13.
Zurück zum Zitat Ginsburg GS, Small DM, Atkinson D. Microemulsion of phospholipids and cholesterol esters protein-free models of low density lipoprotein. J Biol Chem. 1982;257:8216–27.PubMed Ginsburg GS, Small DM, Atkinson D. Microemulsion of phospholipids and cholesterol esters protein-free models of low density lipoprotein. J Biol Chem. 1982;257:8216–27.PubMed
14.
Zurück zum Zitat Maranhão RC, César TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH. Metabolic behavior in rats of a nonprotein microemulsion resembling low density lipoprotein. Lipids. 1993;28:691–6.PubMedCrossRef Maranhão RC, César TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH. Metabolic behavior in rats of a nonprotein microemulsion resembling low density lipoprotein. Lipids. 1993;28:691–6.PubMedCrossRef
15.
Zurück zum Zitat Rosowsky A, Forsch RA, Yu CS, Lazarus H, Beardsley GP. Methotrexate analogues. Divergent influence of alkyl chain on the dihydrofolate reductase affinity and cytotoxicity of methotrexate monoesters. J Med Chem. 1984;27:605–9.PubMedCrossRef Rosowsky A, Forsch RA, Yu CS, Lazarus H, Beardsley GP. Methotrexate analogues. Divergent influence of alkyl chain on the dihydrofolate reductase affinity and cytotoxicity of methotrexate monoesters. J Med Chem. 1984;27:605–9.PubMedCrossRef
16.
Zurück zum Zitat Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method. Methods. 2001;25:402–8.PubMedCrossRef Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method. Methods. 2001;25:402–8.PubMedCrossRef
17.
Zurück zum Zitat Tavares ER, Freitas FR, Diament J, Maranhão RC. Reduction of atherosclerotic lesions in rabbits treated with etoposide associated with cholesterol-rich nanoemulsions. Int J Nanomed. 2011;6:2297–304. Tavares ER, Freitas FR, Diament J, Maranhão RC. Reduction of atherosclerotic lesions in rabbits treated with etoposide associated with cholesterol-rich nanoemulsions. Int J Nanomed. 2011;6:2297–304.
18.
Zurück zum Zitat Hall TC, Roberts D, Kessel DH. Methotrexate and folic reductase in human cancer. Eur J Cancer. 1966;2:135–42.PubMedCrossRef Hall TC, Roberts D, Kessel DH. Methotrexate and folic reductase in human cancer. Eur J Cancer. 1966;2:135–42.PubMedCrossRef
19.
Zurück zum Zitat Bonney RJ, Maley F. Effect of methotrexate on thymidylate synthetase in cultured parenchymal cells isolated from regenerating rat liver. Cancer Res. 1975;8:1950–6. Bonney RJ, Maley F. Effect of methotrexate on thymidylate synthetase in cultured parenchymal cells isolated from regenerating rat liver. Cancer Res. 1975;8:1950–6.
20.
Zurück zum Zitat Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65:168–73.PubMed Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65:168–73.PubMed
21.
Zurück zum Zitat Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2008;47:249–55.CrossRef Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2008;47:249–55.CrossRef
22.
Zurück zum Zitat Abolmaali SS, Tamaddon AM, Dinarvand R. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharmacol. 2013. doi:10.1007/s00280-012-2062-0.PubMed Abolmaali SS, Tamaddon AM, Dinarvand R. A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharmacol. 2013. doi:10.​1007/​s00280-012-2062-0.PubMed
23.
Zurück zum Zitat Mello SB, Tavares ER, Bulgarelli A, Bonfá E, Maranhão RC. Intra-articular methotrexate associated to lipid nanoemulsions: anti-inflammatory effect upon antigen-induced arthritis. Int J Nanomed. 2013;8:443–9. Mello SB, Tavares ER, Bulgarelli A, Bonfá E, Maranhão RC. Intra-articular methotrexate associated to lipid nanoemulsions: anti-inflammatory effect upon antigen-induced arthritis. Int J Nanomed. 2013;8:443–9.
24.
Zurück zum Zitat Simonton JH, Gofman JW. Macrophage migration in experimental atherosclerosis. Circulation. 1951;4:557–62.PubMedCrossRef Simonton JH, Gofman JW. Macrophage migration in experimental atherosclerosis. Circulation. 1951;4:557–62.PubMedCrossRef
25.
Zurück zum Zitat Boehm M, Nabel EG. Cell cycle and cell migration: new pieces to the puzzle. Circulation. 2001;103:2879–81.PubMedCrossRef Boehm M, Nabel EG. Cell cycle and cell migration: new pieces to the puzzle. Circulation. 2001;103:2879–81.PubMedCrossRef
26.
Zurück zum Zitat Tsurusawa M, Niwa M, Katano N, Fujimoto T. Methotrexate cytotoxicity as related to irreversible S phase arrest in mouse L1210 leukemia cells. Jpn J Cancer Res. 1990;81:85–90.PubMedCrossRef Tsurusawa M, Niwa M, Katano N, Fujimoto T. Methotrexate cytotoxicity as related to irreversible S phase arrest in mouse L1210 leukemia cells. Jpn J Cancer Res. 1990;81:85–90.PubMedCrossRef
27.
Zurück zum Zitat Kockx MM, De Meyer GR, Muhring J, Jacob W, Bult H, Herman AG. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation. 1998;97:2307–15.PubMedCrossRef Kockx MM, De Meyer GR, Muhring J, Jacob W, Bult H, Herman AG. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation. 1998;97:2307–15.PubMedCrossRef
28.
Zurück zum Zitat Thorp E, Cui D, Schrijvers DM, Kuriakose G, Tabas I. Merkt receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe−/− mice. Arterioscler Thromb Vasc Biol 2008. 1421–1428. Thorp E, Cui D, Schrijvers DM, Kuriakose G, Tabas I. Merkt receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe−/− mice. Arterioscler Thromb Vasc Biol 2008. 1421–1428.
30.
Zurück zum Zitat Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000. doi:10.1084/jem.192.4.565. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000. doi:10.​1084/​jem.​192.​4.​565.
31.
Zurück zum Zitat Kolodgie FD, Burke AP, Farb A, et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol. 2001;16:285–92.PubMedCrossRef Kolodgie FD, Burke AP, Farb A, et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol. 2001;16:285–92.PubMedCrossRef
32.
Zurück zum Zitat Bao L, Li Y, Deng SX, Landry D, Tabas I. Sitosterol-containing lipoproteins trigger free sterol-induced caspase-independent death in ACAT-competent macrophages. J Biol Chem. 2006;44:33635–49.CrossRef Bao L, Li Y, Deng SX, Landry D, Tabas I. Sitosterol-containing lipoproteins trigger free sterol-induced caspase-independent death in ACAT-competent macrophages. J Biol Chem. 2006;44:33635–49.CrossRef
33.
Zurück zum Zitat Shah PK. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc Med. 1998;3:199–206.PubMed Shah PK. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc Med. 1998;3:199–206.PubMed
34.
Zurück zum Zitat Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926–33.PubMedCrossRef Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926–33.PubMedCrossRef
35.
Zurück zum Zitat Qin W, Lu Y, Zhan C, Shen T, Dou L, Man Y, et al. Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p(53), Bcl-2 and Bcl-xL. Cardiovasc Drugs Ther. 2012. doi:10.1007/s10557-011-6347-z.PubMed Qin W, Lu Y, Zhan C, Shen T, Dou L, Man Y, et al. Simvastatin suppresses apoptosis in vulnerable atherosclerotic plaques through regulating the expression of p(53), Bcl-2 and Bcl-xL. Cardiovasc Drugs Ther. 2012. doi:10.​1007/​s10557-011-6347-z.PubMed
36.
Zurück zum Zitat Almeida CP, Vital CG, Contente TC, Maria DA, Maranhão RC. Modification of composition of a nanoemulsion with different cholesteryl ester molecular species: Effects on stability, peroxidation, and cell uptake. Int J Nanomed. 2010;5:679–86. Almeida CP, Vital CG, Contente TC, Maria DA, Maranhão RC. Modification of composition of a nanoemulsion with different cholesteryl ester molecular species: Effects on stability, peroxidation, and cell uptake. Int J Nanomed. 2010;5:679–86.
37.
Zurück zum Zitat Ridker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep. 2013;15:295.PubMedCrossRef Ridker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep. 2013;15:295.PubMedCrossRef
38.
Zurück zum Zitat Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost. 2009;7 Suppl 1:332–9.PubMedCrossRef Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost. 2009;7 Suppl 1:332–9.PubMedCrossRef
39.
Zurück zum Zitat Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernán MA, Ridker PM, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108:1362–70.PubMedCrossRef Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernán MA, Ridker PM, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108:1362–70.PubMedCrossRef
40.
Zurück zum Zitat Fukuo Y, Nagashima M, Saitoh A, Kobayashi Y, Terashi A, Nakama K, et al. Effects of simvastatin on serum lipids and atherosclerosis in WHHL rabbits. Clin Ther. 1991;13:417–24.PubMed Fukuo Y, Nagashima M, Saitoh A, Kobayashi Y, Terashi A, Nakama K, et al. Effects of simvastatin on serum lipids and atherosclerosis in WHHL rabbits. Clin Ther. 1991;13:417–24.PubMed
Metadaten
Titel
Anti-Atherogenic Effects of Methotrexate Carried by a Lipid Nanoemulsion That Binds to LDL Receptors in Cholesterol-fed Rabbits
verfasst von
Adriana Bulgarelli
Antonio C. A. Leite Jr
Adriana A. M. Dias
Raul C. Maranhão
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 6/2013
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-013-6488-3

Weitere Artikel der Ausgabe 6/2013

Cardiovascular Drugs and Therapy 6/2013 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.